ConvaTec Group PLC
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ConvaTec Group PLC
With valuations down and borrowing costs up, many industry insiders are expecting Darwinian scenes in biotech this year. Survival of the fittest is the order of the day: companies with riskier, less commercially defined propositions will struggle, while platform companies with multiple shots on strong goals will increasingly find favor in a more risk-averse environment.
The French firm will use the funds to establish proof-of-concept for two gene therapy programs in a rare eye condition as it strives to become a world leader in ophthalmic genomic medicine, its CEO tells Scrip.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
ConvaTec will pay $125m upfront for Memphis-based Triad, plus up to $50m in short-term milestone payments and up to $275m more contingent on Triad’s financial performance over the next two years.
- Drug Delivery
- Consumables, Central Supplies
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Rehabilitation Equipment and Devices
- Surgical Equipment & Devices
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Hospitak, Inc.
- Maersk Medical
- Unomedical a/s
- Woodbury Holdings
- ConvaTec, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.